Hepatic resection of metastatic testicular carcinoma: A further update

Tara L. Hahn, Lewis Jacobson, Lawrence H. Einhorn, Richard Foster, Robert J. Goulet

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Background: The goal of this study was to update the multidisciplinary review of patients who underwent resection of hepatic metastases of nonseminomatous germ cell testicular carcinoma at the Indiana University Medical Center. Methods: The study involved retrospective chart review for 57 patients who underwent hepatic resection for treatment of metastatic nonseminomatous testicular carcinoma between June 1974 and May 1996. Patients were categorized according to the worst postchemotherapy pathologic diagnosis. Results: Chemotherapy has been highly effective in curing testicular carcinoma. However, even with platinum-based chemotherapy, one- third of patients either do not achieve complete cures or experience relapses. Since 1965, only 57 of the 2219 patients who underwent postchemotherapy retroperitoneal lymph node dissections for treatment of testicular carcinoma at our center underwent hepatic resection for treatment of metastatic disease. Because teratomas have the propensity to degenerate into sarcomas and can cause symptoms resulting from compression, these lesions must be resected to achieve cures. In addition, the only chance for survival for patients with active disease but normal serum marker levels is with complete resection of the tumor burden. Conclusions: We conclude that hepatic resection for treatment of metastatic testicular carcinoma is safe and efficacious for all patients except those with elevated marker levels after preoperative chemotherapy.

Original languageEnglish (US)
Pages (from-to)640-644
Number of pages5
JournalAnnals of Surgical Oncology
Volume6
Issue number7
DOIs
StatePublished - Jan 1 1999

Fingerprint

Carcinoma
Liver
Drug Therapy
Teratoma
Therapeutics
Platinum
Tumor Burden
Lymph Node Excision
Germ Cells
Sarcoma
Retrospective Studies
Biomarkers
Neoplasm Metastasis
Recurrence
Survival

Keywords

  • Hepatic resection
  • Testicular carcinoma

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Hepatic resection of metastatic testicular carcinoma : A further update. / Hahn, Tara L.; Jacobson, Lewis; Einhorn, Lawrence H.; Foster, Richard; Goulet, Robert J.

In: Annals of Surgical Oncology, Vol. 6, No. 7, 01.01.1999, p. 640-644.

Research output: Contribution to journalArticle

Hahn, Tara L. ; Jacobson, Lewis ; Einhorn, Lawrence H. ; Foster, Richard ; Goulet, Robert J. / Hepatic resection of metastatic testicular carcinoma : A further update. In: Annals of Surgical Oncology. 1999 ; Vol. 6, No. 7. pp. 640-644.
@article{b3575bbc3ba140d39b7a10da86fdbb23,
title = "Hepatic resection of metastatic testicular carcinoma: A further update",
abstract = "Background: The goal of this study was to update the multidisciplinary review of patients who underwent resection of hepatic metastases of nonseminomatous germ cell testicular carcinoma at the Indiana University Medical Center. Methods: The study involved retrospective chart review for 57 patients who underwent hepatic resection for treatment of metastatic nonseminomatous testicular carcinoma between June 1974 and May 1996. Patients were categorized according to the worst postchemotherapy pathologic diagnosis. Results: Chemotherapy has been highly effective in curing testicular carcinoma. However, even with platinum-based chemotherapy, one- third of patients either do not achieve complete cures or experience relapses. Since 1965, only 57 of the 2219 patients who underwent postchemotherapy retroperitoneal lymph node dissections for treatment of testicular carcinoma at our center underwent hepatic resection for treatment of metastatic disease. Because teratomas have the propensity to degenerate into sarcomas and can cause symptoms resulting from compression, these lesions must be resected to achieve cures. In addition, the only chance for survival for patients with active disease but normal serum marker levels is with complete resection of the tumor burden. Conclusions: We conclude that hepatic resection for treatment of metastatic testicular carcinoma is safe and efficacious for all patients except those with elevated marker levels after preoperative chemotherapy.",
keywords = "Hepatic resection, Testicular carcinoma",
author = "Hahn, {Tara L.} and Lewis Jacobson and Einhorn, {Lawrence H.} and Richard Foster and Goulet, {Robert J.}",
year = "1999",
month = "1",
day = "1",
doi = "10.1007/s10434-999-0640-0",
language = "English (US)",
volume = "6",
pages = "640--644",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "7",

}

TY - JOUR

T1 - Hepatic resection of metastatic testicular carcinoma

T2 - A further update

AU - Hahn, Tara L.

AU - Jacobson, Lewis

AU - Einhorn, Lawrence H.

AU - Foster, Richard

AU - Goulet, Robert J.

PY - 1999/1/1

Y1 - 1999/1/1

N2 - Background: The goal of this study was to update the multidisciplinary review of patients who underwent resection of hepatic metastases of nonseminomatous germ cell testicular carcinoma at the Indiana University Medical Center. Methods: The study involved retrospective chart review for 57 patients who underwent hepatic resection for treatment of metastatic nonseminomatous testicular carcinoma between June 1974 and May 1996. Patients were categorized according to the worst postchemotherapy pathologic diagnosis. Results: Chemotherapy has been highly effective in curing testicular carcinoma. However, even with platinum-based chemotherapy, one- third of patients either do not achieve complete cures or experience relapses. Since 1965, only 57 of the 2219 patients who underwent postchemotherapy retroperitoneal lymph node dissections for treatment of testicular carcinoma at our center underwent hepatic resection for treatment of metastatic disease. Because teratomas have the propensity to degenerate into sarcomas and can cause symptoms resulting from compression, these lesions must be resected to achieve cures. In addition, the only chance for survival for patients with active disease but normal serum marker levels is with complete resection of the tumor burden. Conclusions: We conclude that hepatic resection for treatment of metastatic testicular carcinoma is safe and efficacious for all patients except those with elevated marker levels after preoperative chemotherapy.

AB - Background: The goal of this study was to update the multidisciplinary review of patients who underwent resection of hepatic metastases of nonseminomatous germ cell testicular carcinoma at the Indiana University Medical Center. Methods: The study involved retrospective chart review for 57 patients who underwent hepatic resection for treatment of metastatic nonseminomatous testicular carcinoma between June 1974 and May 1996. Patients were categorized according to the worst postchemotherapy pathologic diagnosis. Results: Chemotherapy has been highly effective in curing testicular carcinoma. However, even with platinum-based chemotherapy, one- third of patients either do not achieve complete cures or experience relapses. Since 1965, only 57 of the 2219 patients who underwent postchemotherapy retroperitoneal lymph node dissections for treatment of testicular carcinoma at our center underwent hepatic resection for treatment of metastatic disease. Because teratomas have the propensity to degenerate into sarcomas and can cause symptoms resulting from compression, these lesions must be resected to achieve cures. In addition, the only chance for survival for patients with active disease but normal serum marker levels is with complete resection of the tumor burden. Conclusions: We conclude that hepatic resection for treatment of metastatic testicular carcinoma is safe and efficacious for all patients except those with elevated marker levels after preoperative chemotherapy.

KW - Hepatic resection

KW - Testicular carcinoma

UR - http://www.scopus.com/inward/record.url?scp=0032749838&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032749838&partnerID=8YFLogxK

U2 - 10.1007/s10434-999-0640-0

DO - 10.1007/s10434-999-0640-0

M3 - Article

C2 - 10560848

AN - SCOPUS:0032749838

VL - 6

SP - 640

EP - 644

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 7

ER -